Recent advance of fluorescent probes for detection of drug-induced liver injury markers

被引:21
|
作者
Sun, Dongqin [1 ]
Chen, Zhenzhen [1 ]
Hu, Jiali [1 ]
Zeng, Huajin [1 ]
Qu, Lingbo [2 ]
Yang, Ran [2 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
[2] Zhengzhou Univ, Coll Chem, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
Fluorescent probe; Drug-induced liver injury (DILI); Roussel uclaf causality assessment method (RUCAM); Clinical markers; Imaging; GLUTATHIONE-S-TRANSFERASE; IMAGING ENDOGENOUS PEROXYNITRITE; HIGHLY SELECTIVE DETECTION; ALANINE AMINOTRANSFERASE; INDUCED HEPATOTOXICITY; ENDOPLASMIC-RETICULUM; BIOLUMINESCENT PROBE; CAUSALITY ASSESSMENT; HYPOCHLOROUS ACID; ADVERSE REACTIONS;
D O I
10.1016/j.cclet.2021.12.043
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Drug-induced liver injury (DILI) is a common and serious adverse drug reaction. At present, DILI is perfectly diagnozed in clinical settings using Roussel Uclaf causality assessment method (RUCAM) in its original version published 1993 and its updated version published 2016, well established worldwide as a diagnostic algorithm with a high sensitivity and specificity. Nevertheless, the search for additional detection methods supporting RUCAM continues. In recent years, with the development of optical imaging technology, fluorescent probes have gradually shown great advantages in the detection and diagnosis of DILI markers such as high sensitivity, anti-interference, real-time monitoring and non-invasive measurement. In this review, the recent advances of fluorescent probes for evaluation of DILI in experimental studies were summarized according to various markers of DILI. We believe that learning about the design and practical application of these probes will contribute to the further development of detection sensors for DILI markers. (C) 2022 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
引用
收藏
页码:4478 / 4494
页数:17
相关论文
共 50 条
  • [31] Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
    Fu, Siyu
    Wu, Dongbo
    Jiang, Wei
    Li, Juan
    Long, Jiang
    Jia, Chengyao
    Zhou, Taoyou
    FRONTIERS IN PHARMACOLOGY, 2020, 10
  • [32] Mechanisms of drug-induced liver injury
    Stephens, Camilla
    Andrade, Raul J.
    Isabel Lucena, M.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 14 (04) : 286 - 292
  • [33] Biomarkers for drug-induced liver injury
    Shi, Qiang
    Hong, Huixiao
    Senior, John
    Tong, Weida
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (02) : 225 - 234
  • [34] Signatures in drug-induced liver injury
    Tillmann, Hans L.
    Rockey, Don C.
    CURRENT OPINION IN GASTROENTEROLOGY, 2020, 36 (03) : 199 - 205
  • [35] The pathogenesis of drug-induced liver injury
    Lee, Sun-Jae
    Lee, Youn Ju
    Park, Kwan-Kyu
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (10) : 1175 - 1185
  • [36] Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?
    Teschke, Rolf
    Danan, Gaby
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (04) : 425 - 438
  • [37] Idiosyncratic Drug-Induced Liver Injury: A Short Review
    Yamashita, Yo-ichi
    Imai, Katsunori
    Mima, Kosuke
    Nakagawa, Shigeki
    Hashimoto, Daisuke
    Chikamoto, Akira
    Baba, Hideo
    HEPATOLOGY COMMUNICATIONS, 2017, 1 (06) : 494 - 500
  • [38] Incidence and risk factors of drug-induced liver injury
    Li, Xiaoyun
    Tang, Jieting
    Mao, Yimin
    LIVER INTERNATIONAL, 2022, 42 (09) : 1999 - 2014
  • [39] Drug-induced chronic liver injury
    Dakhoul, Lara
    Ghabril, Marwan
    Chalasani, Naga
    JOURNAL OF HEPATOLOGY, 2018, 69 (01) : 248 - 250
  • [40] Rechallenge in drug-induced liver injury: the attractive hazard
    Andrade, Raul J.
    Robles, Mercedes
    Lucena, Maria Isabel
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (06) : 709 - 714